Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910-918.
Zeuzem S, Ghalib R, K. Reddy R, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1-13.
Zeuzem S, Feld J, Wang S. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract 253]. In: The Liver Meeting 2016. The Liver Meeting 2016. Boston, MA; 2016.
Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-181.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
Zuckerman E, Ashkenasi E, Kovaleve Y, et al. The real world Israeli experience of treating chronic hepatitis C genotype 1 patients with advanced fibrosis with parataprevir/ ritonavir/ ombitasvir, dasabuvir with or without ribavirin: a large, multi-center cohort. J Hepatology. 2016;64(2):S137.
Øvrehus ALH, Blach S, Christensen PB, et al. Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years [P074]. J Hepatol. 2015;62(Suppl 2):S591-S592.